Literature DB >> 7902078

Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues.

E Stahl1, E Mutschler, U Baumgartner, H Spahn-Langguth.   

Abstract

Carvedilol, a lipophilic beta-adrenoceptor antagonist with vasodilating activities, is characterized by a high as well as stereoselective metabolic clearance and distribution volume. Tissue distribution of carvedilol enantiomers and their conjugates were determined under steady-state conditions in rats (p.o., 10 mg/kg, repetitive dosage; n = 5) and after single i.v. administration in control rats and rats with surgical portacaval shunt (pcs) (10 mg/kg; n = 3 each group). In addition, in vitro plasma protein binding was evaluated. The plasma protein binding of carvedilol in rats is > 98% for total plasma (tp) and > 96% for rat serum albumin (rsa) solution (4%), with enantioselectivity ratios of 1.53 (tp) and 1.27 (rsa). Significantly higher unbound fractions were observed in pcs rats, in part due to reduced protein concentrations. In contrast to plasma, where a preponderance of the R-enantiomer with an S/R ratio of 0.6 was found, S-carvedilol was predominant in all tissues (heart, liver, kidneys, lung, spleen, muscle, and adipose tissue), with S/R ratios of 1.3-1.4 in most of these tissues and 2.3 in liver. This preferential tissue partitioning of S-carvedilol was in accordance with its higher unbound fraction in plasma. Carvedilol accumulated predominantly in the highly perfused and/or eliminating organs liver, kidneys, and lung (tissue/plasma ratios; lung: S 76, R 34; liver: S 21, R 5; kidney: S 8, R 3). A similarly enantioselective distribution into the heart of control as well as pcs rats was observed, where the S-enantiomer concentrations exceeded the plasma concentrations 7-fold.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902078     DOI: 10.1002/ardp.19933260907

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  6 in total

1.  Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.

Authors:  Dong Guo; Hong Yang; Qing Li; Hyo Jung Bae; Obinna Obianom; Sujuan Zeng; Tong Su; James E Polli; Yan Shu
Journal:  Pharm Res       Date:  2018-09-06       Impact factor: 4.200

2.  Inhibition of hyperpolarization-activated cyclic nucleotide-gated channels by β-blocker carvedilol.

Authors:  Ying Cao; Shujun Chen; Yemei Liang; Ting Wu; Jianxin Pang; Shuwen Liu; Pingzheng Zhou
Journal:  Br J Pharmacol       Date:  2018-09-09       Impact factor: 8.739

3.  Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release.

Authors:  Qiang Zhou; Jianmin Xiao; Dawei Jiang; Ruiwu Wang; Kannan Vembaiyan; Aixia Wang; Chris D Smith; Cuihong Xie; Wenqian Chen; Jingqun Zhang; Xixi Tian; Peter P Jones; Xiaowei Zhong; Ang Guo; Haiyan Chen; Lin Zhang; Weizhong Zhu; Dongmei Yang; Xiaodong Li; Ju Chen; Anne M Gillis; Henry J Duff; Heping Cheng; Arthur M Feldman; Long-Sheng Song; Michael Fill; Thomas G Back; S R Wayne Chen
Journal:  Nat Med       Date:  2011-07-10       Impact factor: 53.440

4.  Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability.

Authors:  Facundo Martín Bertera; Julieta Sofía Del Mauro; Diego Chiappetta; Ariel Héctor Polizio; Fabián Buontempo; Carlos Alberto Taira; Christian Höcht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-03       Impact factor: 3.000

5.  Non-β-blocking R-carvedilol enantiomer suppresses Ca2+ waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure.

Authors:  Jingqun Zhang; Qiang Zhou; Chris D Smith; Haiyan Chen; Zhen Tan; Biyi Chen; Alma Nani; Guogen Wu; Long-Sheng Song; Michael Fill; Thomas G Back; S R Wayne Chen
Journal:  Biochem J       Date:  2015-07-08       Impact factor: 3.857

6.  UHPLC Enantiomer Resolution for the ɑ/β-Adrenoceptor Antagonist R/S-Carvedilol and Its Major Active Metabolites on Chiralpak IB N-5.

Authors:  Liza Samir; Rasha Hanafi; Sami El Deeb; Hilde Spahn-Langguth
Journal:  Molecules       Date:  2022-08-05       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.